Top Markets
Coin of the day
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM
Xếp hạng trong cổ phiếu #27148
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Giá cổ phiếu
$1.11
Vốn hóa thị trường
$34.83M
Thay đổi (1 ngày)
0.53%
Thay đổi (1 năm)
-32.32%
Quốc gia
US
Giao dịch Actinium Pharmaceuticals, Inc. (ATNM)

Danh mục

Lịch sử lợi suất cổ tức của Actinium Pharmaceuticals, Inc. (ATNM)
Lợi suất cổ tức (TTM) của Actinium Pharmaceuticals, Inc. (mã cổ phiếu: ATNM) tại thời điểm 2026 là: 0
Lợi suất cổ tức trung bình trong 5 năm qua: 0.00%
Lịch sử lợi suất cổ tức của Actinium Pharmaceuticals, Inc. (ATNM) từ 2026 đến 2026
Lợi suất cổ tức vào cuối mỗi năm (TTM)
Năm Lợi suất cổ tức Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.
Lợi suất cổ tức (TTM) của các công ty tương tự hoặc đối thủ
Công ty Lợi suất cổ tức Quốc gia
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US